Li Xian, Xu Xu, Li Jingyun, Huang Yanran, Wang Chengshuo, Zhang Yuan, Zhang Luo
Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China.
Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.
Clin Transl Allergy. 2022 Apr 16;12(4):e12148. doi: 10.1002/clt2.12148. eCollection 2022 Apr.
Chronic rhinitis is generally classified as either allergic rhinitis (AR) or non-allergic rhinitis (NAR). There is currently no report on the economic burden of AR and NAR in Beijing, China.
A total of 1013 valid questionnaires from 448 AR patients and 565 NAR patients living in Beijing were continuously collected for investigation of the direct (e.g., drugs, medical visits) and indirect costs (absenteeism and presenteeism) from August 2020 to April 2021.
The total cost of AR and NAR was € 195.6 patient/year and € 185.3 patient/year respectively. The total societal cost for adult AR and NAR patients in Beijing is around € 440.9 and € 671.9 million per year in terms of the standardized prevalence of the diseases. The patient's level of education, disease duration, predilection time of disease, severity of symptoms and comorbidity with other allergic disease were factors that affected the economic burden on patients with rhinitis.
慢性鼻炎通常分为变应性鼻炎(AR)和非变应性鼻炎(NAR)。目前在中国北京尚无关于AR和NAR经济负担的报告。
2020年8月至2021年4月,连续收集了居住在北京的448例AR患者和565例NAR患者的1013份有效问卷,以调查直接成本(如药物、就诊)和间接成本(旷工和出勤主义)。
AR和NAR的总成本分别为195.6欧元/患者/年和185.3欧元/患者/年。就疾病的标准化患病率而言,北京成年AR和NAR患者的社会总成本每年约为4.409亿欧元和6.719亿欧元。患者的教育水平、病程、疾病好发时间、症状严重程度以及与其他过敏性疾病的合并症是影响鼻炎患者经济负担的因素。